A- A A+

Yi-Hsiang Huang (黃怡翔)

Yi-Hsiang Huang(黃怡翔)


  1. 國立陽明大學 臨床醫學研究所 博士
  2. 國立陽明大學 醫學系 學士
經歷 現職:
  1. - 迄今 臺北榮民總醫院 胃腸肝膽科 主任
  2. - 迄今 國立陽明交通大學 臨床醫學研究所 講座教授
  3. - 迄今 國立陽明交通大學 醫學系內科學科 主任
  4. - 迄今 台北榮民總醫院 胃腸肝膽科 主治醫師
  1. - 台灣肝癌醫學會 常務理事
  2. - 台灣腫瘤消融醫學會 常務理事
  3. - 台灣消化系醫學會 理事
  4. - 台灣肝臟研究學會 秘書長
  5. - 中華醫學會 秘書長
  6. - 美國國家衛生研究院 博士後研究
  1. 慢性B型、C型肝炎之治療
  2. 肝硬化及其合併症之治療
  3. 肝癌免疫治療,標靶治療,RFA,微波消融治療
  4. 腹部超音波及消化道內視鏡診斷及治療
  1. 內科專科醫師
  2. 消化系內科專科醫師
  3. 消化系內視鏡專科醫師
  4. 肝癌專科醫師
  5. 肝腫瘤射頻消融專業醫師
  6. 超音波專科醫師
  1. 國語
  2. 英語


1. Lee PC, Wu CJ, Hung YW, Lee CJ, Chi CT, Lee IC, Yu-Lun K, Chou SH, Luo JC, Hou MC, Huang YH.*. Gut microbiota and metabolites associate with outcomes of immune checkpoint inhibitors-treated unresectable hepatocellular carcinoma. J Immunother Cancer 2022 Jun;10(6):e004779. (*corresponding author)

2. Hsu CH, Huang YH#, Lin SM, Hsu C. AXL and MET in hepatocellular carcinoma: a systematic literature review. Liver Cancer 2022;11(2):94–112 (#co-first author)

3. Chen MH*, Lee IC, Chen MH, Hou MC, Tsai CY, Huang YH*. Abatacept is second to rituximab at risk of HBsAg reverse seroconversion in patients with rheumatic disease. Annals of Rheumatic Diseases 2021 Nov;80(11):1393–1399. (*corresponding author)

4. Lee IC, Huang JY, Chen TC, Yen CH, Chiu NC, Hwang HE, Huang JG, Liu CA, Chau GY, Lee RC, Hung YP, Chao Y, Ho SY*, Huang YH*. Evolutionary Learning Derived Clinical-Radiomic Models for Predicting Early Recurrence of Hepatocellular Carcinoma After Resection. Liver Cancer. 2021;10(6):572-582. (*corresponding author)

5. Hung YW, Lee IC*, Chi CT, Lee RC, Liu CA, Chiu NC, Hwang HE, Chao Y, Hou MC,  Huang YH*. Redefining Tumor Burden in Patients with Intermediate Stage Hepatocellular Carcinoma: the Seven-Eleven Criteria. Liver Cancer. 2021;10(6):629-640. (*corresponding author)

6. Chi CT, Chen CY*, Su CW, Chen PY, Chu CJ, Lan KH, Lee IC, Hou MC, Huang YH*. Direct-acting Antivirals for Patients with Chronic Hepatitis C and Hepatocellular Carcinoma in Taiwan. J Microbiol Immunol Infect 2021 Jun; 54(3):385-395. (*corresponding author)

7. Chen MH, Chen MH, Chou CT, Hou MC, Tasi CY*, Huang YH*. Low but Long-lasting Risk of Reversal of Seroconversion in Patients With Rheumatoid Arthritis Receiving Immunosuppressive Therapy. Clin Gastroenterol Hepatol. 2020 Oct;18(11):2573–2581 (*corresponding author)

8. Lee PC, Chao Y, Chen MH, Lan KH, Lee IC, Hou MC, Huang YH*. Risk of HBV reactivation in patients with immune checkpoint inhibitor-treated unresectable hepatocellular carcinoma. J ImmunoTher Cancer 2020 Aug;8(2):e001072 (*corresponding author)

9. Lee IC, Hung YW, Liu CA, Lee RC, Su CW, Huo TI, Li CP, Chao Y, Lin HC, Hou MC, Huang YH*. A New ALBI-based Model to Predict Survival After Transarterial Chemoembolization for BCLC Stage B Hepatocellular Carcinoma. Liver Int. 2019;39:1704–1712. (*corresponding author)

10. Lee IC, Yang SS, Lee CJ, Su CW, Wang YJ, Lan KH, Lin HC, Hou MC, Peng CY*, Huang YH*. Incidence and Predictors of HBsAg Loss After Peginterferon Therapy in HBeAg-negative Chronic Hepatitis B: A Multicenter, Long-term Follow-up Study. J Infect Dis 2018 Aug 24;218(7):1075-1084 (*corresponding author)

11. Lee PC, Chen YT, Chao Y, Huo TI, Li CP, Su CW, Lee MH, Hou MC, Lee FY, Lin HC, Huang YH*. Validation of the ALBI grade-based integrated model as a predictor for sorafenib-failed hepatocellular carcinoma. Liver Int. 2018 Feb;38(2):321-330 (*corresponding author)

12. Chen MH, Chen MH, Liu CY, Tsai CY, Huang DF, Lin HY, Lee MH,* Huang YH*. Hepatitis B Virus Reactivation in Rheumatoid Arthritis Patients undergoing Biologics Treatment. J Infect Dis 2017 Feb;215 (4): 566-573 (*corresponding author)

13. Lee KC, Lin HC, Huang YH*, Hung SC*. Allo-transplantation of Mesenchymal Stem Cells Attenuates Hepatic Injury through IL1Ra Dependent Macrophage Switch in a Mouse Model of Liver Disease. J Hepatol 2015 Dec;63(6):1405-1412  (*corresponding author)

14.  Huang YH*, Hsiao LT, Hong YC, Chiou TJ, Yu YB, Gau JP, Liu CY, Yang MH, Tzeng CH, Lee PC, Lin HC, Lee SD. Randomized Controlled Trial of Entecavir Prophylaxis for Rituximab-associated Hepatitis B Virus Reactivation in Patients with Lymphoma and Resolved Hepatitis B. J Clin Oncol 2013 Aug;31(22):2765-2772. (*first and corresponding author)

15.  Lee IC, Huang YH*, Chau GY, Huo TI, Su CW, Wu JC, Lin HC. Serum Interferon Gamma Level Predicts Recurrence in Hepatocellular Carcinoma Patients After Curative Treatments. Int J Cancer 2013 Dec; 133: 2895–2902. (*corresponding author)

16.  Lee IC, Huo TI, Huang YH*, Chao Y, Li CP, Lee PC, Chiang JH, Su CW, Lan KH, Yang CM, Wu JC, Lin HC, Lee SD. Trans-arterial Chemo-embolization Can Prolong Survival for Patients with Metastatic Hepatocellular Carcinoma: A Propensity Score Matching Analysis. Hepatol Int. 2012 Oct;6(4):753-762 (*corresponding author)

17.  Lee IC, Huang YH*, Chan CC, Huo TI, Chu CJ, Lai CR, Lee PC, Su CW, Wu JC, Lin HC, Lee SD. Impact of body mass index and viral load on liver histology in hepatitis B e antigen-negative chronic hepatitis B. Clinical Nutrition 2011 Oct;30:647-652  (*corresponding author)

18.  Lee IC, Huang YH*, Chan CC, Huo TI, Chu CJ, Lai CR, Lee PC, Su CW, Hung HH,  Wu JC, Lin HC, Lee SD. Correlation between clinical indication for treatment and liver histology in HBeAg-negative chronic hepatitis B: a novel role of alpha-fetoprotein. Liver Int. 2010 Sep;30(8):1161-1168 (*corresponding author)

19.  Huang YH*, Wu JC, Peng WL, Huo TI, Shih HH, Lan KH, Su CW, Lee SD. Generation of Cytotoxicity against Hepatitis Delta Virus Genotypes and Quasispecies by Epitope Modification. J Hepatol 2009 Apr;50:779-788  (*corresponding author)

20.  Huang YH, Wu JC*, Chen SC, Chen CH, Chiang JH, Huo TI, Lee PC, Chang FY, Lee SD. Survival Benefit of Transcatheter Arterial Chemoembolization in Patients with Hepatocellular Carcinoma larger than 10cm in Diameter. Aliment Pharmacol Ther 2006 Jan;23:129-135

21.  Huang YH, Chen CH, Chang TT, Chen SC, Chiang JH, Lee HS, Lin PW, Huang GT, Sheu JC, Tsai HM, Lee PC, Huo TI, Lee SD, Wu JC*. The role of transcatheter arterial embolization for patients with unresectable hepatocellular carcinoma: a nation-wide, multi-center study evaluated by cancer stages. Aliment Pharmacol Ther 2005 Mar;21:687-694

22.  Huang YH, Chen CH, Chang TT, Chen SC, Wang SY, Lee PC, Lee HS, Lin PW, Huang GT, Sheu JC, Tsai HM, Chau GY, Chiang JH, Lui WY, Lee SD, Wu JC*. The role of transcatheter arterial embolization in patients with resectable hepatocellular carcinoma: a nation-wide, multi-center study. Liver Int 2004 Oct;24:419-424

23.  Huang YH, Wu JC*, Hsu SC, Syu WJ. Varied immunity generated in mice by DNA vaccines with large and small hepatitis delta antigens. J Virol 2003;77:12980-12985

24.  Huang YH, Wu JC*, Tao MH, Syu WJ, Hsu SC, Chi WK, Chang FY, Lee SD. DNA-based immunization produced Th1 immune responses to hepatitis delta virus in a mouse model. Hepatology 2000 July;32:104-110